Metallo-β-lactamases of non-fermenting Gram-negative bacteria

Reviews and Research in Medical Microbiology

Volumn 14, Issue 3, 2003, Pages 79-93

  Zong, Zhiyong ^a   Lü, Xiaoju ^a   Gao, Yanyu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acinetobacter baumannii; Antibiotic resistance; Carbapenem; Flavobacteriaceae; Metallo lactamases; Non fermenting bacteria; Pseudomonas aeruginosa; Stenotrophomonas maltophilia

Indexed keywords

BETA LACTAMASE; CARBAPENEM; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BLAB GENE; EBR 1 GENE; FERMENTATION MONITORING; FLAVOBACTERIUM; GENE; GOB GENE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HYDROLYSIS; IMP 1 GENE; IND 1 GENE; L1 GENE; MUS 1 GENE; NUCLEOTIDE SEQUENCE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STENOTROPHOMONAS MALTOPHILIA; STRAIN DIFFERENCE; TUS 1 GENE;

EID: 0242269420     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-200307000-00002     Document Type: Review

References (82)

1. Govan JR. Pseudomonads and non-fermenters. In: Medical Microbiology, 15th edn. Edited by Greenwood D, Slack R, Peutherer J. London: Pearson Professional Limited; 1997:284-289.
2. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002, 8:321-331.
3. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Invest Drugs 2002, 3:218-224.
4. Navarro F, Miro E. Updated on CTX-M-type β-lactamases. Rev Med Microbiol 2002, 13:63-73.
5. Fernandez-Cuenca F, Martinez-Martinez L, Conejo Mf MC, Ayala JA, Perea EJ, Pascual A. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003, 51:565-574.
6. Zong ZY, Lü XJ, Gao YY. Aeromonas hydrophilia infections: clinical aspects and therapeutic options. Rev Med Microbiol 2002, 13:151-162.
7. Bush K, Jacoby G, Medeiros AA. A functional classification for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995, 39:1211-1233.
8. Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 1997, 41:223-232.
9. Ambler RP. The structure of β-lactamase. Philos Trans R Soc B Biol Sci 1980, 289:321-331.
10. Bellais S, Aubert D, Naas T, Nordmann P. Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing β-lactamases in Chryseobacterium meningosepticum. Antimicrob Agents Chemother 2000, 44:1878-1886.
11. Woodford N, Palepou MI, Babini GS, Holmes B, Livermore DM. Carbapenemases of Chryseobacterium (Flavobacterium) meningosepticum: Distribution of blaB and characterization of a novel metallo-β-lactamase gene, blaB3, in the type strain, NCTC 10016. Antimicrob Agents Chemother 2000, 44:1448-1452.
12. Naas T, Bellais S, Nordmann P. Molecular and biochemical characterization of a carbapenem-hydrolysing β-lactamase from Flavobacterium johnsoniae. J Antimicrob Chemother 2003, 51:267-273.
13. Bellais S, Poirel L, Leotard S, Naas T, Nordmann P. genetic diversity of carbapenem-hydrolyzing metallo-β-lactamases from Chryseobacterium (Flavobacterium) indologenes. Antimicrob Agents Chemother 2000, 44:3028-3034.
14. Mammeri H, Bellais S, Nordmann P. Chromosome-encoded β-lactamases TUS-1 and MUS-1 from Myroides odoratus and Myroides odoratimimus (formerly Flavobacterium odoratum), new members of the lineage of molecular subclass B1 metallo enzymes. Antimicrob Agents Chemother 2002, 46:3561-3567.
15. Bellais S, Naas T, Nordmann P. Genetic and biochemical characterization of CGB-1, an Ambler class B carbapenem-hydrolyzing β-lactamase from Chryseobacterium gleum. Antimicrob Agents Chemother 2002, 46:2791-2796.
16. Bicknell R, Emanuel EL, Gagnon J, Waley SG. The production and molecular properties of the zinc β-lactamase of Pseudomonas maltophilia IID 1275. Biochem J 1985, 229:791-797.
17. Walsh TR, Hall L, Assinder SJ, Nichols WW, Cartwright SJ, MacGowan AP, et al. Sequence analysis of the L1 metallo-β-lactamase from Xanthomonas maltophilia. Biochim Biophys Acta 1994, 1218:199-201.
18. Avison MB, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR. Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001, 45:413-419.
19. Avison MB, Higgins CS, Ford PJ, von Heldreich CJ, Walsh TR, Bennett PM. Differential regulation of L1 and L2 β-lactamse expression in Stenotrophomonas maltophilia. J Antimicrob Chemother 2002, 49:387-389.
20. Rossolini GM, Franceschini N, Riccio ML, Mercuri PS, Perilli M, Galleni M, et al. Characterization and sequence of the Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B β-lactamase showing a broad substrate profile. Biochem J 1998, 332:145-152.
21. Vessillier S, Docquier J-D, Rival S, Frere JM, Galleni M, Amicosante G, et al. Overproduction and biochemical characterization of the Chryseobacterium meningosepticum BlaB metallo-beta-lactamase. Antimicrob Agents Chemother 2002, 46:1921-1927.
22. Di Pentima MC, Mason EO Jr., Kaplan SL. In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options. Clin Infect Dis 1998, 26:1169-11676.
23. Yano H, Kuga A, Okamoto R, Kitasato H, Kobayashi T, Inoue M. Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother 2001, 45:1343-1348.
24. Bellais S, Leotard S, Poirel L, Naas T, Nordmann P. Molecular characterization of a carbapenem-hydrolyzing beta-lactamase from Chryseobacterium (Flavobacterium) indologenes. FEMS Microbiol Lett 1999, 171:127-132.
25. Sato K, Fujii T, Okamoto R, Inoue M, Mitsuhashi S. Biochemical properties of β-lactamase produced by Flavobacterium odoratum. Antimicrob Agents Chemother 1985, 27:612-614.
26. Bellais S, Girlich D, Karim A, Nordmann P. EBR-1, a novel Ambler subclass B1 β-lactamase from Empedobacter brevis. Antimicrob Agents Chemother 2002, 46:3223-3227.
27. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991, 35:147-151.
28. Gibb AL, Tribuddharat C, Moore RC, Louie TJ, Krulicki W, Livermore DM, et al. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002, 46:255-258.
29. Lombardi G, Luzzaro F, Docquier JD, Riccio ML, Perilli M, Colì A, et al. Nosocomial infections caused by multidrug-resistant isolates of Pseudomonas putida producing VIM-1 metallo-β-lactamase. J Clin Microbiol 2002, 40:4051-4055.
30. Tsakris A, Pournaras S, Woodford N, Palepou MI, Babini GS, Douboyas J, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-2 carbapenemase in Greece. J Clin Microbiol 2000, 38:1290-1292.
31. IMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes. Antimicrob Agents Chemother 1999, 43:890-901.
32. VIM-2 gene cassettes. J Antimicrob Chemother 2002, 49:837-840.
33. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo J-D, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000, 44:891-897.
34. VIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob Agents Chemother 2001, 45:546-552.
35. Riccio ML, Pallecchi L, Fontana R, Rossolini GM. In70 of plasmid pA532, a blaVIM-1-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother 2001, 45:1249-1253.
36. Senda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, et al. Multifocal outbreaks of metallo-β-lactamase producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996, 40:349-353.
37. IMP) in gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol 1996, 34:2909-2913.
38. IMP. Antimicrob Agents Chemother 1998, 42:2006-2011.
39. Takahashi A, Yomoda S, Kobayashi I, Okubo T, Tsunoda M, Iyobe S. Detection of carbapenemase-producing Acinetobacter baumannii in a hospital. J Clin Microbiol 2000, 38:526-529.
40. Tysall L, Stockdale MW, Chadwick PR, Palepou MF, Towner KJ, Livermore DM, et al. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the United Kingdom. J Antimicrob Chemother 2002, 49:217-218.
41. IMP allelic variants carried by gene cassettes of different phylogeny. Antimicrob Agents Chemother 2000, 44:1229-1235.
42. Chu YW, Afzal-Shah M, Houang ET, Palepou MI, Lyon DJ, Woodford N, et al. IMP-4, a novel metallo-β-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother 2001, 45:710-714.
43. (IMP-5), a new integron-borne metallo-β-lactamase gene from an Acinetobacter baumannii nosocomial isolate in Portugal. FEMS Microbiol Lett 2002, 215:33-39.
44. Ho SE, Subramaniam G, Palasubramaniam S, Navaratnam P. Carbapenem-resistant Pseudomonas aeruginosa in Malaysia producing IMP-7 β-lactamase [letter]. Antimicrob. Agents Chemother 2002, 46:3286-3287.
45. Hawkey PM, Xiong J, Chen H, Ye H, Lai F, Wei Y, et al. Appearance and dissemination of a novel transferable IMP-9 metallo-β-lactamase in Pseudomonas aeruginosa strains from Guangzhou, PRC. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 2001 [abstract 2226].
46. Iyobe S, Kusadokoro H, Takahashi A, Yomoda S, Okubo T, Nakamura A, et al. Detection of a variant metallo-β-lactamase, IMP-10, from two unrelated strains of Pseudomonas aeruginosa and an Alcaligenes xylosoxidans strain. Antimicrob Agents Chemother 2002, 46:2014-2016.
47. Docquier J-D, Riccio ML, Mugnaioli C, Luzzaro F, Endimiani A, Toniolo A, et al. IMP-12, a new plasmid-encoded metallo-β-lactamase from a Pseudomonas putida clinical isolate. Antimicrob Agents Chemother 2003, 47:1522-1528.
48. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, et al. Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 1999, 43:1584-1590.
49. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase. Clin Infect Dis 2000, 31:1119-1125.
50. Giakkoupi P, Petrikkos G, Tzouvelekis LS, Tsonas S, Legakis NJ, Vatopoulos AC. Spread of integron-associated VIM-type metallo-β-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J Clin Microbiol 2003, 41:822-825.
51. Mavroidi A, Tsakris A, Tzelepi E, Pournaras S, Loukova V, Tzouvelekis LS. Carbapenem-hydrolysing VIM-2 metallo-β-lactamase in Pseudomonas aeruginosa from Greece. J Antimicrob Chemother 2000, 46:1041-1042.
52. VIM-2-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-β-lactamase. FEMS Microbiol Lett 2001, 195:145-150.
53. Cardoso O, Leitao R, Figueiredo A, Sousa JC, Duarte A, Peixe LV. Metallo-β-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal. Microb Drug Resist 2002, 8:93-97.
54. Prats G, Miro E, Mirelis B, Poirel L, Bellais S, Nordmann P. First Isolation of a carbapenem-hydrolyzing β-lactamase in Pseudomonas aeruginosa in Spain [letter]. Antimicrob Agents Chemother 2002, 46:932-933.
55. VIM-2 in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program. J Antimicrob Chemother 2003, 52:116-119.
56. Lee K, Lim JB, Yum JH, Yong D, Chong YS, Kim JM, et al. blaVIM-2 cassette-containing novel Integrons in Metallo-β-Lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002, 46:1053-1058.
57. Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, et al. Metallo-β-lactamases in clinical isolates in Taiwan and identification of VIM-3, a novel variant of VIM-2 enzyme. Antimicrob Agents Chemother 2001, 45:2224-2228.
58. Franceschini N, Caravelli B, Docquier J-D, Galleni M, Frère J-M, Amicosante G, et al. Purification and biochemical characterization of the VIM-1 metallo-β-lactamase. Antimicrob Agents Chemother 2000, 44:3003-3007.
59. VIM-1 in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002, 46:4026-4028.
60. Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN, et al. Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2002, 50:673-679.
61. Baxter IA, Lambert PA. Isolation and partial purification of a carbapenem-hydrolysing metallo-β-lactamase from Pseudomonas cepacia. FEMS Microbiol Lett 1994, 122:251-256.
62. Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998, 27(Suppl 1):S117-S124.
63. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001, 47:247-250.
64. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001, 45:480-484.
65. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999, 43:424-427.
66. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998, 27(Suppl 1):S93-S99.
67. Dubois V, Poirel L, Marie C, Arpin C, Nordmann P, Quentin C. Molecular characterization of a novel class I integron containing bla(GES-1) and a fused product of aac3-lb/aac6′-lb′ gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002, 46:638-645.
68. Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa. J Antimicrob Chemother 2002, 49:561-565.
69. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991, 35:147-151.
70. Iyobe S, Yamada H, Minami S. Insertion of a carbapenemase gene cassette into an integron of a Pseudomonas aeruginosa plasmid [Letter]. J Antimicrob Chemother 1996, 38:1114-1115.
71. Payne DJ, Cramp R, Bateson JH, Neale J, Knowles D. Rapid identification of metallo- and serine β-lactamases. Antimicrob Agents Chemother 1994, 38:991-996.
72. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11:57-80.
73. Paton R, Miles RS, Amyes SG. Biochemical properties of inducible β-lactamases produced from Xanthomonas maltophilia. Antimicrob Agents Chemother 1994, 38:2143-2149.
74. Cullmann W. Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates. Chemotherapy 1991, 37:246-250.
75. Saika T, Kobayashi I, Hasegawa M, Nishida M. Antimicrobial resistance and DNA-fingerprinting pattern of Burkholderia cepacia blood isolates. J Infect Chemother 2002, 8:341-344.
76. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999, 43:213-217.
77. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996, 9:148-165.
78. Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol 2002, 40:4776-4778.
79. Gales AC, Tognim MC, Reis AO, Jones RN, Sader HS. Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. Diagn Microbiol Infect Dis 2003, 45:77-79.
80. Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 2001, 39:3942-3945.
81. Bellais S, Poirel L, Naas T, Girlich D, Nordmann P. Genetic-biochemical analysis and distribution of the Ambler class A β-lactamase CME-2, responsible for extended-spectrum cephalosporin resistance in Chryseobacterium (Flavobacterium) meningosepticum. Antimicrob Agents Chemother 2000, 44:1-9.
82. Bellais S, Naas T, Nordmann P. Molecular and biochemical characterization of Ambler class A extended-spectrum β-lactamase CGA-1 from Chryseobacterium gleum. Antimicrob Agents Chemother 2002, 46:966-970.